GLMD_OUT_1 [2025-04-28 12:52:55 -0400] 5783 Bytes | 1566 tokens | Cum: 1566 tkns (19.57% of 8k)
==========================================================================

Listen up, partner—it's 12:52 PM on Mon Apr 28, 2025, and I’m revved up about Galmed Pharmaceuticals (GLMD), climbing from $1.57 to $1.87. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Galmed Pharmaceuticals (GLMD)
IPO: 2014-03-13 (11 Years Ago)
Market Cap: $3,161,248
Shares Outstanding: 2,260,000
Exchange: XNAS
Description: Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Here’s a list of headlines for Galmed Pharmaceuticals:

Today 08:00AM - Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
Apr-17-25 08:30AM - Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
Apr-15-25 08:30AM - Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
Apr-10-25 08:00AM - Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
Apr-02-25 04:10PM - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
Mar-20-25 08:55AM - Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
Nov-15-24 08:29AM - Galmed Pharmaceuticals: Q3 Earnings Snapshot
Sep-25-24 08:00AM - Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Sep-20-24 09:00AM - How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Sep-19-24 07:00AM - Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Jun-22-24 09:52AM - GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024
Apr-10-24 06:30AM - Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
Apr-05-24 09:53AM - GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023
Apr-04-24 05:06PM - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Mar-15-24 09:00AM - Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Nov-21-23 07:32AM - Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Nov-20-23 04:32PM - Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Sep-26-23 08:30AM - Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
Sep-22-23 04:05PM - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Aug-10-23 11:08AM - Galmed Pharmaceuticals: Q2 Earnings Snapshot
Jul-14-23 09:20AM - Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
Jul-10-23 08:00AM - Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-17T12:30:00Z - Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
B2 - 2025-04-15T12:30:00Z - Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
B3 - 2024-07-09T09:33:25Z - Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Mainz Biomed ... - Benzinga
B4 - 2024-04-10T12:12:43Z - Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
B5 - 2024-04-08T17:10:02Z - Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
B6 - 2024-04-08T09:15:51Z - Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Galmed Pharmaceuticals (GLMD).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

GLMD_OUT_3 [2025-04-28 12:52:56 -0400] 802 Bytes | 199 tokens | Cum: 1767 tkns (22.09% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/04/n44861808/galmed-pharmaceuticals-launches-vcu-collaboration-to-tackle-drug-resistance-in-gi-cancersGalmed Pharmaceuticals has launched a collaboration with Virginia Commonwealth University to investigate its drug Aramchol's potential in overcoming drug resistance in gastrointestinal cancers, including colorectal and liver cancers.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GLMD_OUT_5 [2025-04-28 12:52:57 -0400] 1006 Bytes | 289 tokens | Cum: 2058 tkns (25.72% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T13:56:24Z - Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings - CG Oncology (NASDAQ:CGON), Domino'...
A2 - 2025-04-17T13:00:04Z - Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers By Investi...
A3 - 2025-04-17T12:30:00Z - Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers...
A4 - 2025-04-17T12:30:00Z - Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - Galmed P...
A5 - 2025-04-10T12:15:00Z - Galmed Reports Positive Part 1 Results From AM-001 Study Of Aramchol Meglumine...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GLMD_OUT_7 [2025-04-28 12:52:58 -0400] 1181 Bytes | 358 tokens | Cum: 2418 tkns (30.23% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings - CG Oncology (NASDAQ:CGON), Domino's Pizza (NASDAQ:DPZ)**Date: 2025-04-28Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/04/45039697/dow-jumps-over-150-points-dominos-pizza-posts-upbeat-earningsU.S. stocks traded higher this morning, with the Dow Jones index more than 150 points on Monday.

Following the market opening Monday, the Dow traded up 0.47% to 40,300.68 while the NASDAQ rose 0.13% to 17,405.94. The S&P 500 also rose, gaining, 0.31% to 5,542.29.

Check This Out: Top 3 Health Care Stocks That May Rocket Higher In April

Leading and Lagging Sectors

Industrials shares jumped by 0.7% on Monday.

In trading on Monday, information technology fell by 0.4%.

Top Headline

Domino's Pizza, Inc. DPZ reported better-than-expected earnings for its first quarter on

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GLMD_OUT_9 [2025-04-28 12:52:59 -0400] 1181 Bytes | 307 tokens | Cum: 2727 tkns (34.09% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): Monday.

The company posted quarterly earnings of $4.33 per share which beat the analyst consensus estimate of $4.07 per share. The company reported quarterly sales of $1.11 billion which missed the analyst consensus estimate of $1.13 billion.

Equities Trading UP

Galmed Pharmaceuticals Ltd. GLMD shares shot up 47% to $2.32. Galmed signed a term sheet for the development of novel semaglutide sublingual formulation. Shares of CG Oncology, Inc. CGONgot a boost, surging 36% to $30.47 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting. NaaS Technology Inc. NAAS shares were also up, gaining 53% to $2.75. NaaS Technology, last week, announced a 1-for-800 ADS ratio change.

Equities Trading DOWN

Spruce Biosciences, Inc. SPRB shares dropped 31% to $0.09 after the company announced it approved a pl

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GLMD_OUT_11 [2025-04-28 12:52:59 -0400] 1181 Bytes | 356 tokens | Cum: 3085 tkns (38.56% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): an to implement a workforce reduction. Shares of Pineapple Financial Inc. PAPL were down 17% to $0.2241. Protara Therapeutics, Inc. TARA was down, falling 24% to $3.30 as the company announced interim results highlighting durable clinical responses with TARA-002 In high-risk NMIBC.

Commodities

In commodity news, oil traded down 0.2% to $62.92 while gold traded up 0.3% at $3,306.70.

Silver traded down 0.3% to $32.91 on Monday, while copper rose 0.4% to $4.9120.

Euro zone

European shares were higher today. The eurozone's STOXX 600 gained 0.7%, Germany's DAX 40 gained 0.7% and France's CAC 40 gained 1%. Spain's IBEX 35 Index gained 0.7%, while London's FTSE 100 rose 0.4%.

Asia Pacific Markets

Asian markets closed mixed on Monday, with Japan's Nikkei 225 surging 0.38%, China's Shanghai Composite falling 0.20%, Hong Kong's Hang Seng Index falling 0.04% and India's BSE Sensex gaining 1.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GLMD_OUT_13 [2025-04-28 12:53:00 -0400] 976 Bytes | 296 tokens | Cum: 3383 tkns (42.29% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): 27%.

The Dallas Fed manufacturing index will be released today.

Now Read This:

Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday.

Photo via Shutterstock

CGONCG Oncology Inc$30.6437.0%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum12.06Growth-Quality-Value0.99Price TrendShortMediumLongOverviewDPZDomino's Pizza Inc$476.27-2.32%GLMDGalmed Pharmaceuticals Ltd$2.3449.0%NAASNaas Technology Inc$2.91538.2%PAPLPineapple Financial Inc$0.2387-11.9%SPRBSpruce Biosciences Inc$0.0945-27.2%TARAProtara Therapeutics Inc$3.35-22.4%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GLMD_OUT_15 [2025-04-28 12:53:01 -0400] 238 Bytes | 59 tokens | Cum: 3444 tkns (43.05% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GLMD_OUT_17 [2025-04-28 12:53:02 -0400] 251 Bytes | 78 tokens | Cum: 3525 tkns (44.06% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

GLMD_OUT_19 [2025-04-28 12:53:08 -0400] 4925 Bytes | 1184 tokens | Cum: 4712 tkns (58.90% of 8k)
==========================================================================

This is our set of metrics for Galmed Pharmaceuticals.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-------------------+
| Volume: 56,506,284 | Perf Month: 9.90% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 867.59K | Perf Quarter: -35.44% | Short Float: 4.34% | ROE: -49.77% |
+---------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 128.84 | Index: - | Short Ratio: 0.11 | ROI: -46.04% |
+---------------------+-----------------------+------------------------+-------------------+
| RSI (14): 59.37 | Market Cap: 4.17M | Short Interest: 0.10M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-------------------+
| ATR (14): 0.25 | Shs Outstand: 2.26M | Beta: 0.45 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+-------------------+
| SMA20: 28.63% | Shs Float: 2.22M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-------------------+
| SMA50: -0.55% | Inst Own: 9.39% | Sales past 5Y: 0.00% | Earnings: Mar 26 |
+---------------------+-----------------------+------------------------+-------------------+
| SMA200: -42.85% | Insider Own: 1.72% | Employees: 6 | |
+---------------------+-----------------------+------------------------+-------------------+
| Perf Week: 31.88% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading by Galmed Pharmaceuticals officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.8689
Average Volume: 2927805.05
30-Day High: 1.8689
30-Day Low: 1.24
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Galmed Pharmaceuticals (GLMD).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Galmed Pharmaceuticals.

2) MARKET_SCORE[]
This conversation was initiated because GLMD is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for GLMD.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, GLMD could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect GLMD to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Galmed Pharmaceuticals.

11) ETHICAL_RATING[]
Rate Galmed Pharmaceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Galmed Pharmaceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

GLMD_IN_21 [2025-04-28 12:53:09 -0400] 126 Bytes | 29 tokens | Cum: 4957 tkns (61.96% of 8k)
==========================================================================

====================================
[2025-04-28 12:53:09] # Analysis Completed
Elapsed Time: 14.38 seconds